Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

The University of Rochester Wilmot Cancer Institute last week was named the 73rd NCI-designated cancer center. Now, New York State has eight NCI-designated cancer centers. Only California has more—ten.

Even light daily physical activity linked to lower cancer risk, NIH and Oxford study shows

In a prospective cohort study of more than 85,000 adults in the UK, researchers at the NIH and University of Oxford found that individuals who engaged in light- and moderate-to-vigorous-intensity daily physical activity had a lower risk of cancer than individuals who were more sedentary.

March 28, 2025

Vol.51 No.12

Drugs & Targets

FDA approves cabozantinib for patients 12 and up with pNET and epNET

FDA approved cabozantinib (Cabometyx) for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors and well-differentiated extra-pancreatic neuroendocrine tumors.

March 28, 2025

Vol.51 No.12

Drugs & Targets

FDA approves prostate cancer imaging agent Gozellix

FDA approved Gozellix (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), a next-generation PSMA-PET imaging agent for prostate cancer.

March 28, 2025

Vol.51 No.12

Guest Editorial

Caught in the crossfire: The critical threats facing cancer centers, research, and patient care

NCI-designated cancer centers and academic medical institutions (AMCs) are facing unprecedented threats that jeopardize their ability to conduct groundbreaking research, deliver cutting-edge care, and sustain clinical trials essential to patient treatment.

March 21, 2025

Vol.51 No.11

By Shannon McWeeney and Sorena Nadaf-Rahrov

Guest Editorial

Rathmell: We need a “March Madness” for cancer research
“Cancer is a tremendously challenging tournament, but we are in it to win”

Although this column is running in The Cancer Letter, where we turn for timely insights and information relevant to the cancer community, I suspect that a lot of our readers are watching college basketball this week.

March 21, 2025

Vol.51 No.11

By W. Kimryn Rathmell

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit

Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

YOU MAY BE INTERESTED IN

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

Even light daily physical activity linked to lower cancer risk, NIH and Oxford study shows

FDA approves cabozantinib for patients 12 and up with pNET and epNET

FDA approves prostate cancer imaging agent Gozellix

Caught in the crossfire: The critical threats facing cancer centers, research, and patient care

Rathmell: We need a “March Madness” for cancer research
“Cancer is a tremendously challenging tournament, but we are in it to win”

Renew today!

Subscriber content

Never miss an issue!

Login

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit

Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

YOU MAY BE INTERESTED IN

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

Even light daily physical activity linked to lower cancer risk, NIH and Oxford study shows

FDA approves cabozantinib for patients 12 and up with pNET and epNET

FDA approves prostate cancer imaging agent Gozellix

Caught in the crossfire: The critical threats facing cancer centers, research, and patient care

Rathmell: We need a “March Madness” for cancer research“Cancer is a tremendously challenging tournament, but we are in it to win”

Never miss an issue!

Login

Rathmell: We need a “March Madness” for cancer research
“Cancer is a tremendously challenging tournament, but we are in it to win”